|
Obesity
|
0.200 |
Biomarker
|
disease |
RGD |
One of the most striking findings of this study was that significant changes of Ehd1 and laminin receptor in BAT as well as antiquitin, DJ-1 protein, and paraoxonase 2 in WAT were found for the first time in obese rats.
|
21365757 |
2011 |
|
Non-Small Cell Lung Carcinoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
In this study, EHD1 depletion significantly increased NSCLC cell sensitivity to EGFR-TKI, which was accompanied by EMT reversal.
|
31740781 |
2020 |
|
Non-Small Cell Lung Carcinoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
Xenograft tumor models were used to investigate the role of EHD1 in NSCLC tumor growth.
|
31023336 |
2019 |
|
Non-Small Cell Lung Carcinoma
|
0.050 |
GeneticVariation
|
disease |
BEFREE |
We found that EHD1 was an important factor in EGFR-TKI resistance and the cancer stem-like cell phenotype of lung cancer, and these results suggest that targeting the NF-κB/miR-590/EHD1 pathway has potential therapeutic promise in EGFR-mutant NSCLC patients with acquired EGFR-TKI resistance.
|
29549343 |
2018 |
|
Non-Small Cell Lung Carcinoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
EHD1 knockdown inhibited the invasion and migration of human NSCLC cells, and overexpression of EHD1 increased the metastatic potential of lung cancer cells.
|
27531895 |
2017 |
|
Non-Small Cell Lung Carcinoma
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
The immunohistochemistry assay showed that adjuvant chemotherapy-treated NSCLC patients expressing EHD1 exhibited reduced OS compared with patients who did not express EHD1 (P = 0.01).
|
27411790 |
2016 |
|
Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
Xenograft tumor models were used to investigate the role of EHD1 in NSCLC tumor growth.
|
31023336 |
2019 |
|
Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
PAST: The role of post-mastectomy radiotherapy (PMRT) in patients with tumor <5 cm and one to three positive lymph nodes after axillary dissection (ALND) is vigorously debated.
|
31561088 |
2019 |
|
Neoplasms
|
0.040 |
AlteredExpression
|
group |
BEFREE |
To identify novel NF-pNET-associated antigens, we performed serological identification of antigens by recombinant cDNA expression cloning (SEREX) and identified five tumor antigens (phosphatase and tensin homolog, EP300-interacting inhibitor of differentiation 3 [EID3], EH domain-containing protein 1, galactoside-binding soluble 9, and BRCA1-associated protein).
|
29290942 |
2017 |
|
Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
We conclude that EHD1 is required for tumour growth and that it is a regulator of CDDP accumulation and cytotoxicity.
|
27411790 |
2016 |
|
Malignant Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
Inhibiting EHD1 could potentially slow cancer invasiveness and metastasis, and these cyclic peptides represent the most potent inhibitors of EHD1 to date.
|
28951093 |
2018 |
|
Malignant Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
We found that EHD1 was an important factor in EGFR-TKI resistance and the cancer stem-like cell phenotype of lung cancer, and these results suggest that targeting the NF-κB/miR-590/EHD1 pathway has potential therapeutic promise in EGFR-mutant NSCLC patients with acquired EGFR-TKI resistance.
|
29549343 |
2018 |
|
Neoplasm Metastasis
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
Inhibiting EHD1 could potentially slow cancer invasiveness and metastasis, and these cyclic peptides represent the most potent inhibitors of EHD1 to date.
|
28951093 |
2018 |
|
Malignant neoplasm of lung
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
The overexpression of EHD1 markedly increased erlotinib resistance and lung cancer cell stemness in vitro and in vivo.
|
29549343 |
2018 |
|
Carcinoma of lung
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
The overexpression of EHD1 markedly increased erlotinib resistance and lung cancer cell stemness in vitro and in vivo.
|
29549343 |
2018 |
|
Primary malignant neoplasm
|
0.020 |
Biomarker
|
group |
BEFREE |
Inhibiting EHD1 could potentially slow cancer invasiveness and metastasis, and these cyclic peptides represent the most potent inhibitors of EHD1 to date.
|
28951093 |
2018 |
|
Primary malignant neoplasm
|
0.020 |
Biomarker
|
group |
BEFREE |
We found that EHD1 was an important factor in EGFR-TKI resistance and the cancer stem-like cell phenotype of lung cancer, and these results suggest that targeting the NF-κB/miR-590/EHD1 pathway has potential therapeutic promise in EGFR-mutant NSCLC patients with acquired EGFR-TKI resistance.
|
29549343 |
2018 |
|
Primary malignant neoplasm of lung
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
The overexpression of EHD1 markedly increased erlotinib resistance and lung cancer cell stemness in vitro and in vivo.
|
29549343 |
2018 |
|
Multiple Sclerosis
|
0.020 |
Biomarker
|
disease |
BEFREE |
Due to the lack of prospective studies with longitudinal data on relapse, past genetic studies have not attempted to identify genetic factors that predict relapse risk (the primary endpoint of many pivotal clinical trials testing the efficacy of multiple sclerosis (MS) disease-modifying drugs) at a genome-wide scale.
|
28739605 |
2017 |
|
Neoplasm Metastasis
|
0.020 |
AlteredExpression
|
phenotype |
BEFREE |
We demonstrated that upregulation of EHD1 is associated with lymph nodes metastasis and unfavorable survival in patients with NSCLC.
|
27531895 |
2017 |
|
Malignant neoplasm of lung
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
These results provide a model to illustrate the relationship between EHD1 expression and lung cancer metastasis, opening up new avenues for the prognosis and therapy of lung cancer.
|
27531895 |
2017 |
|
Carcinoma of lung
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
These results provide a model to illustrate the relationship between EHD1 expression and lung cancer metastasis, opening up new avenues for the prognosis and therapy of lung cancer.
|
27531895 |
2017 |
|
Primary malignant neoplasm of lung
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
These results provide a model to illustrate the relationship between EHD1 expression and lung cancer metastasis, opening up new avenues for the prognosis and therapy of lung cancer.
|
27531895 |
2017 |
|
Multiple Sclerosis
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Detailed studies of the natural history of untreated multiple sclerosis (MS) have been carried out in London, Ontario, Canada, over the past generation.
|
16170495 |
2005 |
|
Osteosarcoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
EHD1 expression [P = 0.020; HR, 5.582; 95% confidence intervals (CI), 1.314-23.72] was an independent prognostic indicator of DFS in osteosarcoma patients; tumor size and EHD1 expression of osteosarcomas were independent prognostic indicators of OS in osteosarcoma patients.
|
30975166 |
2019 |